发布求助
文献互助 智能选刊 最新文献

Pharmacogenomics最新文献

筛选
英文 中文
Characterization of CYP2C19 pharmacogenetic variation in African populations and comparison with other global populations. CYP2C19在非洲人群中的药物遗传变异特征及其与其他全球人群的比较。
IF 2.1 4区 医学
Pharmacogenomics Pub Date : 2023-11-01 Epub Date: 2023-11-06 DOI: 10.2217/pgs-2023-0166
Ross P Booyse, David Twesigomwe, Scott Hazelhurst
{"title":"Characterization of <i>CYP2C19</i> pharmacogenetic variation in African populations and comparison with other global populations.","authors":"Ross P Booyse, David Twesigomwe, Scott Hazelhurst","doi":"10.2217/pgs-2023-0166","DOIUrl":"10.2217/pgs-2023-0166","url":null,"abstract":"<p><p><b>Background:</b> <i>CYP2C19</i> is important in the metabolism of clopidogrel and several antidepressants. This study aimed to characterize the distribution of <i>CYP2C19</i> star alleles (haplotypes) across diverse African populations compared with global populations. <b>Methods:</b> <i>CYP2C19</i> star alleles and diplotypes were called from high coverage genomes using the StellarPGx pipeline. <b>Results:</b> <i>CYP2C19*1</i> (51%), <i>*2</i> (17%) and <i>*17</i> (22%) were the most common star alleles across African populations in this study. It was observed that 3% of African participants had potentially novel <i>CYP2C19</i> haplotypes. <b>Conclusion:</b> This study supports the necessity for <i>CYP2C19</i> pharmacogenetic testing in African and global clinical settings, as well as the importance of comprehensive star allele characterization in the African context.</p>","PeriodicalId":20018,"journal":{"name":"Pharmacogenomics","volume":null,"pages":null},"PeriodicalIF":2.1,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10694788/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71484927","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Pharmacogenomics of chloroquine and hydroxychloroquine: current evidence and future implications. 氯喹和羟氯喹的药物基因组学：当前证据和未来意义。
IF 2.1 4区 医学
Pharmacogenomics Pub Date : 2023-10-01 Epub Date: 2023-10-17 DOI: 10.2217/pgs-2023-0124
Mohitosh Biswas, Chonlaphat Sukasem
{"title":"Pharmacogenomics of chloroquine and hydroxychloroquine: current evidence and future implications.","authors":"Mohitosh Biswas,&nbsp;Chonlaphat Sukasem","doi":"10.2217/pgs-2023-0124","DOIUrl":"10.2217/pgs-2023-0124","url":null,"abstract":"<p><p>As substrates of CYP2C8, CYP3A4/5 and CYP2D6, chloroquine's (CQ) and hydroxychloroquine's (HCQ) efficacy and safety may be affected by variants in the genes encoding these enzymes. This paper aims to assimilate the current evidence on the pharmacogenomics of CQ/HCQ and to identify risk phenotypes affecting the safety or efficacy of these drugs. It has been found that some <i>CYP3A5</i>, <i>CYP2D6</i> and <i>CYP2C8</i> genetic variants may affect the safety or effectiveness of CQ/HCQ. The phenotypes predictively representing ultra-rapid and poor metabolizers have been considered high-risk phenotypes. After considering these high-risk phenotypes in different ethnic groups, it is predicted that a considerable proportion of patients taking CQ/HCQ may be at risk of either therapeutic failure or severe toxicities.</p>","PeriodicalId":20018,"journal":{"name":"Pharmacogenomics","volume":null,"pages":null},"PeriodicalIF":2.1,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41237624","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Pharmacogenomic variants affecting efficacy and toxicity of statins in a south Asian population from Sri Lanka. 斯里兰卡南亚人群中影响他汀类药物疗效和毒性的药物基因组变异
IF 2.1 4区 医学
Pharmacogenomics Pub Date : 2023-10-01 Epub Date: 2023-10-25 DOI: 10.2217/pgs-2023-0149
Priyanga Ranasinghe, Nirmala Sirisena, Jeremy N Ariadurai, Thuwaragesh Vishnukanthan, Sathsarani Thilakarathne, Gayani Anandagoda, Vajira Hw Dissanayake
{"title":"Pharmacogenomic variants affecting efficacy and toxicity of statins in a south Asian population from Sri Lanka.","authors":"Priyanga Ranasinghe,&nbsp;Nirmala Sirisena,&nbsp;Jeremy N Ariadurai,&nbsp;Thuwaragesh Vishnukanthan,&nbsp;Sathsarani Thilakarathne,&nbsp;Gayani Anandagoda,&nbsp;Vajira Hw Dissanayake","doi":"10.2217/pgs-2023-0149","DOIUrl":"10.2217/pgs-2023-0149","url":null,"abstract":"<p><p><b>Aim:</b> To describe the diversity of pharmacogenetic variants of statins among Sri Lankans. <b>Materials & methods:</b> Variant data of relevant genes were obtained from an anonymized database of 426 Sri Lankans. Minor allele frequencies (MAFs) were compared with published data from other populations. <b>Results:</b> The MAF of <i>SLCO1B1*5</i> (rs4149056 [T>C]) was 18.19% (95% CI: 14.53-21.85). MAFs of <i>CYP2C9*2</i> (rs1799853 [C>T]) and <i>CYP2C9*3</i> (rs1057910 [A>C]) were 2.58% (95% CI: 1.08-4.08) and 10.30% (95% CI: 7.75-13.61), respectively. MAFs of rs2231142 (G>T) (<i>ABCG2</i>), rs7412 (C>T) (<i>APOE</i>) and rs20455 (A>G) (<i>KIF6</i>) variants were 10.68% (95% CI: 7.76-13.60), 3.52% (95% CI: 1.77-5.27) and 50.7% (95% CI: 45.96-55.45), respectively. Compared with western/other Asian populations, rs20455 (A>G), <i>CYP2C9*3</i> (A>C) and <i>SLCO1B1*5</i> (T>C) variants were significantly higher in Sri Lankans. <b>Conclusion:</b> Variants that affect efficacy of statins (<i>KIF6</i> [rs20455], <i>CYP2C9*3</i>) and increase risk of statin-induced myotoxicity (<i>SLCO1B1*5</i> and <i>CYP2C9*3</i>) were prevalent in higher frequencies among Sri Lankans compared with western populations.</p>","PeriodicalId":20018,"journal":{"name":"Pharmacogenomics","volume":null,"pages":null},"PeriodicalIF":2.1,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"50158543","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Retrospective pharmacogenetic study in a cohort of pediatric tuberous sclerosis complex patients using everolimus. 使用依维莫司的儿童结节性硬化症患者队列的回顾性药物遗传学研究。
IF 2.1 4区 医学
Pharmacogenomics Pub Date : 2023-10-01 Epub Date: 2023-10-23 DOI: 10.2217/pgs-2023-0140
Julia Concha, Estela Sangüesa, Jose Luis Peña, María Pilar Ribate, Cristina Belén García
{"title":"Retrospective pharmacogenetic study in a cohort of pediatric tuberous sclerosis complex patients using everolimus.","authors":"Julia Concha,&nbsp;Estela Sangüesa,&nbsp;Jose Luis Peña,&nbsp;María Pilar Ribate,&nbsp;Cristina Belén García","doi":"10.2217/pgs-2023-0140","DOIUrl":"10.2217/pgs-2023-0140","url":null,"abstract":"<p><p><b>Aim:</b> Tuberous sclerosis complex (TSC) is a rare disease that produces multisystemic disorders. Everolimus (EVR) is the only immunosuppressive drug approved to control the symptoms and progression of the disease. The aim was to evaluate the genotype-phenotype association to improve the pediatric TSC pharmacotherapeutic outcome. <b>Patients & methods:</b> Ten pediatric TSC patients were recruited. Concomitant treatment and main metabolic enzymes and transporter coding gene variants of EVR were analyzed. <b>Results:</b> Significant associations were found between <i>CYP3A4*22</i> allele and concomitant treatment with valproic acid (CYP3A4-inhibitor) with a poor metabolizer phenotype and the presence of pneumonia. <b>Conclusion:</b> This is the first pharmacogenetic study of EVR in pediatric TSC patients. The authors propose to consider concomitant treatment and pharmacogenetics due to their multifactorial status.</p>","PeriodicalId":20018,"journal":{"name":"Pharmacogenomics","volume":null,"pages":null},"PeriodicalIF":2.1,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49691944","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Evaluation of pentamidine tolerability and efficacy between CYP2C19 phenotypes. CYP2C19表型间戊脒耐受性和疗效的评估。
IF 2.1 4区 医学
Pharmacogenomics Pub Date : 2023-10-01 Epub Date: 2023-10-17 DOI: 10.2217/pgs-2023-0093
Alexis Koon, Jiaxian He, Jai Patel, Allison Morse, Victoria Boseman, Alicia Hamilton, Thomas Knight, Nilay Shah, Brittany Ragon, Aleksander Chojecki, Jing Ai, Nury Steuerwald, Jonathan Gerber, Edward Copelan, Michael Grunwald, Justin Arnall
{"title":"Evaluation of pentamidine tolerability and efficacy between <i>CYP2C19</i> phenotypes.","authors":"Alexis Koon,&nbsp;Jiaxian He,&nbsp;Jai Patel,&nbsp;Allison Morse,&nbsp;Victoria Boseman,&nbsp;Alicia Hamilton,&nbsp;Thomas Knight,&nbsp;Nilay Shah,&nbsp;Brittany Ragon,&nbsp;Aleksander Chojecki,&nbsp;Jing Ai,&nbsp;Nury Steuerwald,&nbsp;Jonathan Gerber,&nbsp;Edward Copelan,&nbsp;Michael Grunwald,&nbsp;Justin Arnall","doi":"10.2217/pgs-2023-0093","DOIUrl":"10.2217/pgs-2023-0093","url":null,"abstract":"<p><p>Intravenous pentamidine is used for prophylaxis against <i>Pneumocystis jirovecii</i> pneumonia, an infection seen in hematopoietic stem cell transplant recipients. Pentamidine is partially metabolized by <i>CYP2C19</i>, which is vulnerable to pharmacogenetic variation. This retrospective study evaluated allogeneic hematopoietic stem cell transplant patients who received intravenous pentamidine as <i>P. jirovecii</i> pneumonia prophylaxis. The primary objective was the association between <i>CYP2C19</i> phenotype and discontinuation of pentamidine due to drug-related side effects based on univariate logistic regression (N = 81). Ten patients (12.3%) discontinued pentamidine because of side effects. There was no difference in discontinuation between phenotype groups (p = 0.18) or discontinuation due to side effects (p = 0.76). Overall, no association was seen between phenotypes and pentamidine-related side effects (p = 0.475). Drug discontinuation rates and <i>P. jirovecii</i> pneumonia infection rates were low.</p>","PeriodicalId":20018,"journal":{"name":"Pharmacogenomics","volume":null,"pages":null},"PeriodicalIF":2.1,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41237623","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Challenges for the application of pharmacogenomics associated with the nomenclature of allelic variants. 与等位基因变体命名相关的药物基因组学应用的挑战。
IF 2.1 4区 医学
Pharmacogenomics Pub Date : 2023-10-01 Epub Date: 2023-10-17 DOI: 10.2217/pgs-2023-0160
Nadine de Godoy Torso, Paulo Caleb Jl Santos, Patricia Moriel
{"title":"Challenges for the application of pharmacogenomics associated with the nomenclature of allelic variants.","authors":"Nadine de Godoy Torso,&nbsp;Paulo Caleb Jl Santos,&nbsp;Patricia Moriel","doi":"10.2217/pgs-2023-0160","DOIUrl":"10.2217/pgs-2023-0160","url":null,"abstract":"","PeriodicalId":20018,"journal":{"name":"Pharmacogenomics","volume":null,"pages":null},"PeriodicalIF":2.1,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41237621","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Distribution of pharmacogene allele and phenotype frequencies in Brazilian psychiatric patients. 巴西精神病患者药物基因等位基因和表型频率的分布。
IF 2.1 4区 医学
Pharmacogenomics Pub Date : 2023-09-01 Epub Date: 2023-10-17 DOI: 10.2217/pgs-2023-0075
Guido Boabaid May, Bruna Raquel de Souza, Bárbara Yasmin Gueuvoghlanian-Silva, Esther Camilo Dos Reis, Sofia Rech Mostardeiro, Paula Pedrassani Boabaid May, Elvis Cueva Mateo, Giovanna Grunewald Vietta, Giovana Weber Hoss
{"title":"Distribution of pharmacogene allele and phenotype frequencies in Brazilian psychiatric patients.","authors":"Guido Boabaid May,&nbsp;Bruna Raquel de Souza,&nbsp;Bárbara Yasmin Gueuvoghlanian-Silva,&nbsp;Esther Camilo Dos Reis,&nbsp;Sofia Rech Mostardeiro,&nbsp;Paula Pedrassani Boabaid May,&nbsp;Elvis Cueva Mateo,&nbsp;Giovanna Grunewald Vietta,&nbsp;Giovana Weber Hoss","doi":"10.2217/pgs-2023-0075","DOIUrl":"10.2217/pgs-2023-0075","url":null,"abstract":"<p><p><b>Purpose:</b> This work was designed to identify the pharmacogenetic profile of Brazilian psychiatric patients receiving psychoactive drug treatment according to ethnicity. <b>Methods:</b> Based on the GnTech<sup>®</sup> database, this cross-sectional study analyzed data from self-reported sociodemographic and genetic results from the next-generation sequencing panel composed of 26 pharmacogenes from 359 psychotropic drug users. <b>Results:</b> Variant frequencies of multiple pharmacogenes presented differences between ethnicities (<i>CYP3A5</i>, <i>CYP2D6</i>, <i>CYP1A2</i>, <i>CYP2B6</i>, <i>CYP3A4</i>, <i>UGT1A4</i>, <i>UGT2B15</i>, <i>ABCB1 rs1045642</i>, <i>ADRA2A rs1800544</i>, <i>COMT rs4680</i>, <i>GRIK4 rs1954787</i>, <i>GSK3B rs334558</i>, <i>GSK3B rs6438552</i>, <i>HTR1A rs6295</i>, <i>HTR2A rs7997012</i>, <i>HTR2C rs1414334</i>, <i>MTHFR rs1801131</i>, <i>OPRM1 rs1799971</i> and <i>5-HTTLPR</i>), endorsing the necessity of individual-level analyses in drug treatment. <b>Conclusion:</b> A discussion of pharmacogenomic test implementation in psychiatric clinical practice is needed to improve treatment choices, especially in Brazil, a multiethnic country.</p>","PeriodicalId":20018,"journal":{"name":"Pharmacogenomics","volume":null,"pages":null},"PeriodicalIF":2.1,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41237622","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
HLA-B*57:01 typing in a Malaysian cohort: implications of abacavir hypersensitivity in people living with HIV. 马来西亚队列中的HLA-B*57:01分型：HIV感染者阿巴卡韦超敏反应的意义。
IF 2.1 4区 医学
Pharmacogenomics Pub Date : 2023-09-01 Epub Date: 2023-09-28 DOI: 10.2217/pgs-2023-0136
V Kalidasan, Iswarya Kunalan, Reena Rajasuriar, Vijay Kumar Subbiah, Kumitaa Theva Das
{"title":"<i>HLA-B*57:01</i> typing in a Malaysian cohort: implications of abacavir hypersensitivity in people living with HIV.","authors":"V Kalidasan,&nbsp;Iswarya Kunalan,&nbsp;Reena Rajasuriar,&nbsp;Vijay Kumar Subbiah,&nbsp;Kumitaa Theva Das","doi":"10.2217/pgs-2023-0136","DOIUrl":"10.2217/pgs-2023-0136","url":null,"abstract":"<p><p><b>Background:</b> Abacavir (ABC) in combination with other antiretroviral drugs, is used to treat people living with HIV (PLWH). However, it is linked to a fatal hypersensitivity reaction in susceptible individuals, and is strongly associated with the <i>HLA-B*57:01</i> allele. <b>Materials & methods:</b> A total of 152 patients, 50 PLWH and 102 HIV-1 negative patients, were assessed for the <i>HLA-B*57:01</i> allele through a sequence-specific primer PCR. <b>Results:</b> All PLWH tested negative for the <i>HLA-B*57:01</i> allele, but two HIV-negative patients were found to have <i>HLA-B*57</i>, with one of them expressing the <i>HLA-B*57:01</i> allele. <b>Conclusion:</b> Given the low prevalence of this risk allele in the population, testing for the presence of <i>HLA-B*57:01</i> in PLWH may not provide significant benefit for the reported population.</p>","PeriodicalId":20018,"journal":{"name":"Pharmacogenomics","volume":null,"pages":null},"PeriodicalIF":2.1,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41163341","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Severe systemic adverse reactions to ophthalmic timolol in a CYP2D6 homozygous *4 allele carrier: a case report. CYP2D6纯合子*4等位基因携带者对噻吗洛尔的严重全身性不良反应：一例报告。
IF 2.1 4区 医学
Pharmacogenomics Pub Date : 2023-09-01 Epub Date: 2023-09-15 DOI: 10.2217/pgs-2023-0122
Anna Bollinger, Chiara Jeiziner, Henriette E Meyer Zu Schwabedissen, Kurt E Hersberger, Samuel S Allemann, Céline K Stäuble
{"title":"Severe systemic adverse reactions to ophthalmic timolol in a <i>CYP2D6</i> homozygous <i>*4</i> allele carrier: a case report.","authors":"Anna Bollinger,&nbsp;Chiara Jeiziner,&nbsp;Henriette E Meyer Zu Schwabedissen,&nbsp;Kurt E Hersberger,&nbsp;Samuel S Allemann,&nbsp;Céline K Stäuble","doi":"10.2217/pgs-2023-0122","DOIUrl":"10.2217/pgs-2023-0122","url":null,"abstract":"<p><p>A woman with ocular hypertension suffered from severe bradycardia, hypotension and syncope attacks in temporal relation with ophthalmic timolol application. Topically applied timolol is nasally absorbed and has been shown to reach potentially relevant systemic concentrations. Timolol is mainly metabolized by CYP2D6, which exhibits interindividual metabolic capacity due to genetic variations. A reactive pharmacogenetic panel test identified the patient as a <i>CYP2D6</i> homozygous <i>*4</i> allele carrier, which has been associated with a poor metabolizer phenotype and lacking enzyme activity. Thus, the adverse drug reactions possibly resulted from increased systemic timolol exposure. This case report highlights that pharmacogenetic panel testing can contribute to safe and effective pharmacotherapy, even for topically applied drugs.</p>","PeriodicalId":20018,"journal":{"name":"Pharmacogenomics","volume":null,"pages":null},"PeriodicalIF":2.1,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10243760","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Donor-derived cell free DNA as a biomarker in kidney transplantation. 供体来源的无细胞DNA作为肾移植中的生物标志物。
IF 2.1 4区 医学
Pharmacogenomics Pub Date : 2023-09-01 Epub Date: 2023-09-21 DOI: 10.2217/pgs-2023-0138
Tarek Abdulhadi, Louai Alrata, Casey Dubrawka, Gwendolyn Amurao, Sri Mahathi Kalipatnapu, Che Isaac, Shelden Rodrigues, Karen Marie Flores, Dema Yaseen Alsabbagh, Omar Alomar, Tarek Alhamad
{"title":"Donor-derived cell free DNA as a biomarker in kidney transplantation.","authors":"Tarek Abdulhadi,&nbsp;Louai Alrata,&nbsp;Casey Dubrawka,&nbsp;Gwendolyn Amurao,&nbsp;Sri Mahathi Kalipatnapu,&nbsp;Che Isaac,&nbsp;Shelden Rodrigues,&nbsp;Karen Marie Flores,&nbsp;Dema Yaseen Alsabbagh,&nbsp;Omar Alomar,&nbsp;Tarek Alhamad","doi":"10.2217/pgs-2023-0138","DOIUrl":"10.2217/pgs-2023-0138","url":null,"abstract":"<p><p>The early detection of acute rejection in the allograft is important as it provides an opportunity for timely therapeutic intervention in order to preserve graft function and achieve longer graft survival. Donor-derived cell-free DNA (dd-cfDNA) has emerged as a new biomarker in the field of kidney transplantation. In this review, we used data from various studies to examine the role of dd-cfDNA in comparison to creatinine and donor-specific antibodies in the early detection of transplant rejection. We also reviewed the use of dd-cfDNA in other organ transplants as well as the challenges and potential future direction for dd-cfDNA as a diagnostic tool.</p>","PeriodicalId":20018,"journal":{"name":"Pharmacogenomics","volume":null,"pages":null},"PeriodicalIF":2.1,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41143312","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术官方微信